Does Neffy Work as Well as EpiPen for Anaphylaxis?
Neffy, a nasal spray version of epinephrine approved by the FDA in 2024, matches the effectiveness of injectable epinephrine like EpiPen in clinical trials for treating anaphylaxis. It delivers 2 mg epinephrine per spray (versus 0.3 mg in adult injectors), achieving similar blood levels and symptom relief speed—within minutes—in most patients.[1][2]
How Do Clinical Studies Compare Them?
Phase 3 trials (e.g., ROCKET) tested Neffy on 166 adults and kids over 30 kg during food-induced anaphylaxis. It met primary endpoints: rapid epinephrine absorption (median Tmax 20 minutes, similar to IM injection) and symptom resolution without needing rescue medication in 89% of cases. No head-to-head trials exist, but pharmacokinetic data show bioequivalence, with nasal spray reaching comparable peak concentrations (Cmax) despite higher dosing to account for variable nasal absorption.[1][3]
What Happens If Absorption Is Poor?
Neffy has a key limitation: reduced effectiveness with nasal congestion from anaphylaxis itself. Trials excluded severe blockage cases, and real-world data note up to 30% lower absorption in congested noses. Labels warn of this, recommending injectables as first-line if heavy congestion is present. Still, in mild-moderate cases, it performs equivalently.[2][4]
Is Neffy FDA-Approved for the Same Uses?
Yes, the FDA approved Neffy in August 2024 for emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and children ≥30 kg (66 lbs). It's interchangeable with auto-injectors under the same indications, with no superiority claims but equal regulatory standing.[1][5]
Cost and Availability Differences
Neffy costs $25 out-of-pocket after coupons (versus $600+ for EpiPens without insurance), making it more accessible. It's available by prescription now, with two-dose kits. No patent issues block generics yet; ARS Pharma holds exclusivity until at least 2033.[6][7]
[1]: FDA Approval Summary for Neffy
[2]: NEJM: Phase 3 ROCKET Trial Results
[3]: ARS Pharma Investor Presentation
[4]: Neffy Prescribing Information
[5]: FDA News Release
[6]: GoodRx Pricing Comparison
[7]: DrugPatentWatch: Neffy Patents